Disopyramide

證據等級: L5

預測適應症: 10 個

Disopyramide: From Cardiac Arrhythmia to Tourette Syndrome

One-Sentence Summary

Disopyramide is a Class Ia antiarrhythmic agent internationally used for the treatment and prevention of ventricular arrhythmias, though it holds no registration on the Australian Register of Therapeutic Goods (ARTG). The TxGNN model predicts it may be effective for Tourette Syndrome with a prediction score of 99.86%, however with 0 clinical trials and 0 publications currently supporting this specific direction, the evidence base is extremely limited. This prediction currently sits at the lowest evidence tier (L5) and warrants a Hold recommendation pending basic preclinical investigation.

Quick Overview

Item	Content
Original Indication	Not registered in Australia; internationally recognised as a Class Ia antiarrhythmic for ventricular arrhythmias
Predicted New Indication	Tourette Syndrome
TxGNN Prediction Score	99.86%
Evidence Level	L5
Australia Market Status	Not Marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on established pharmacological knowledge, Disopyramide is a Class Ia antiarrhythmic that works by blocking voltage-gated sodium (Na⁺) channels in cardiac tissue — slowing conduction velocity and prolonging the refractory period. It also carries significant anticholinergic (muscarinic receptor antagonist) activity, which contributes both to its therapeutic profile and its well-known side effect burden.

Tourette syndrome is a neurodevelopmental condition characterised by involuntary motor and vocal tics. Its core pathophysiology involves dysregulation of dopaminergic and cholinergic signalling within the basal ganglia–thalamocortical circuits. The theoretical mechanistic basis for this TxGNN prediction rests on Disopyramide’s anticholinergic properties: muscarinic antagonism could theoretically modulate striatal cholinergic interneurons, which play a role in tic generation. However, this reasoning is highly speculative, and the Na⁺ channel blocking mechanism has no established relevance to Tourette syndrome pathophysiology.

It is important to put the 99.86% prediction score in context. TxGNN’s score reflects graph-level relationship patterns within the biomedical knowledge graph — it does not constitute a mechanistic or clinical prediction. Given the weak biological plausibility and the complete absence of any supporting clinical or preclinical evidence, this prediction should be treated with considerable caution.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

Disopyramide is not currently registered on the Australian Register of Therapeutic Goods (ARTG). No product entries exist for this drug in Australia.

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information. As Disopyramide is not registered in Australia, clinicians should consult international regulatory sources (e.g., US FDA prescribing information, EMA SmPC) for comprehensive safety data. Of particular note for any proposed off-label use: Disopyramide is associated with significant negative inotropic effects, QT prolongation risk, and substantial anticholinergic burden — safety considerations that would require careful evaluation in any non-cardiac patient population.

Conclusion and Next Steps

Decision: Hold

Rationale: The evidence for Disopyramide in Tourette syndrome stands at L5 — model prediction only — with no clinical trials, no published literature, and weak mechanistic plausibility. Compounding this, Disopyramide carries a challenging safety profile (proarrhythmia, negative inotropic effects, anticholinergic burden) that would require strong justification before any off-label use could be considered, and the drug is not currently registered in Australia.

To proceed, the following is needed:

Preclinical studies demonstrating pharmacological activity of Disopyramide — or of Na⁺ channel blockade and/or muscarinic antagonism more broadly — in validated animal models of Tourette syndrome or tic disorders
Mechanistic evidence specifically linking Disopyramide’s anticholinergic or ion channel properties to striatal cholinergic interneuron modulation relevant to tic suppression
A comprehensive safety and tolerability assessment for the Tourette syndrome patient population, which is predominantly paediatric and young adult
Exploration of whether other anticholinergics (e.g., trihexyphenidyl, benztropine) with a cleaner cardiovascular safety profile have shown any signal in tic disorders — as a prerequisite reference point
A TGA registration pathway assessment should any Australian clinical development be contemplated
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.